Abstract
A previously uncharacterized member of the M1 family of zinc metallopeptidases, arginyl aminopeptidase-like 1 (RNPEPL1; EC 3.4.11.1), was cloned and expressed, and the recombinant enzyme characterized. RNPEPL1 was a broad specificity aminopeptidase with preference for a P1 methionine, glutamine, or citrulline residue, and exhibited a broad pH preference, with maximal activity observed between pH 6.6 and 8.0. The enzyme was inhibited by calcium ions but unaffected by chloride ions, and was insensitive to specific inhibitors of the closely-related arginyl aminopeptidase, indicating similarity to leukotriene A4 hydrolase. RT-PCR analysis of RNPEPL1 expression revealed a ubiquitous tissue distribution, consistent with a general housekeeping function, but also revealed alternative splicing of the mRNA in all tissues examined. The inclusion of intron 5 was predicted to result in a truncated protein product, while an alternative 3 ’ splice site of exon 9 of the reference sequence was predicted to result in the omission of a conserved eleven amino acid stretch from the C-terminal domain.
Keywords: alternative splicing, calcium, zinc, protease, metallopeptidase, Aminopeptidase
Protein & Peptide Letters
Title: Arginyl Aminopeptidase-Like 1 (RNPEPL1) Is an Alternatively Processed Aminopeptidase with Specificity for Methionine, Glutamine, and Citrulline Residues
Volume: 16 Issue: 10
Author(s): Michael W. Thompson, Karen A. Beasley, Matthew D. Schmidt and Rebecca L. Seipelt
Affiliation:
Keywords: alternative splicing, calcium, zinc, protease, metallopeptidase, Aminopeptidase
Abstract: A previously uncharacterized member of the M1 family of zinc metallopeptidases, arginyl aminopeptidase-like 1 (RNPEPL1; EC 3.4.11.1), was cloned and expressed, and the recombinant enzyme characterized. RNPEPL1 was a broad specificity aminopeptidase with preference for a P1 methionine, glutamine, or citrulline residue, and exhibited a broad pH preference, with maximal activity observed between pH 6.6 and 8.0. The enzyme was inhibited by calcium ions but unaffected by chloride ions, and was insensitive to specific inhibitors of the closely-related arginyl aminopeptidase, indicating similarity to leukotriene A4 hydrolase. RT-PCR analysis of RNPEPL1 expression revealed a ubiquitous tissue distribution, consistent with a general housekeeping function, but also revealed alternative splicing of the mRNA in all tissues examined. The inclusion of intron 5 was predicted to result in a truncated protein product, while an alternative 3 ’ splice site of exon 9 of the reference sequence was predicted to result in the omission of a conserved eleven amino acid stretch from the C-terminal domain.
Export Options
About this article
Cite this article as:
Thompson Michael W., Beasley Karen A., Schmidt Matthew D. and Seipelt Rebecca L., Arginyl Aminopeptidase-Like 1 (RNPEPL1) Is an Alternatively Processed Aminopeptidase with Specificity for Methionine, Glutamine, and Citrulline Residues, Protein & Peptide Letters 2009; 16 (10) . https://dx.doi.org/10.2174/092986609789071199
DOI https://dx.doi.org/10.2174/092986609789071199 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biocompatibility and Solubility of Fe3O4-BSA Conjugates with Human Blood
Current Nanoscience Integrins and Cancer: Gene Expression, Epigenetics and Metastasis
Current Genomics Intersection of MicroRNA and Gene Regulatory Networks and their Implication in Cancer
Current Pharmaceutical Biotechnology A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Role of Hsp70 in Cancer Growth and Survival
Protein & Peptide Letters Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Control of Tumor Markers Using Nanotechnology
Mini-Reviews in Medicinal Chemistry Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis
Current Pharmaceutical Design HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design L1 Retrotransposon and Retinoblastoma: Molecular Linkages Between Epigenetics and Cancer
Current Molecular Medicine Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery Human Papillomavirus E7 Oncoprotein Promotes Proliferation and Migration through the Transcription Factor E2F1 in Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science A Transporter Gene (Sodium Iodide Symporter) for Dual Purposes in Gene Therapy: Imaging and Therapy
Current Gene Therapy Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure- Based Exploration of SIRT2 Pharmacophoric Space Coupled With QSAR Analyses
Anti-Cancer Agents in Medicinal Chemistry The Anti-Breast Cancer Effects of Green-Synthesized Zinc Oxide Nanoparticles Using Carob Extracts
Anti-Cancer Agents in Medicinal Chemistry